CureSearch

Home » Archives for CureSearch

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman

Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated

FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman Read More »

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that.

Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma

High-risk neuroblastoma in children has a grim outlook. Dr. Jonus is fighting to change that. Read More »

Dr. Hunter Jonus

Pin It on Pinterest

Scroll to Top